Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: A prospective study with the LiMAx test

Transplant International

Volumn 28, Issue 1, 2015, Pages 52-58

  Jara, Maximilian ^a   Malinowski, MacIej ^a   Lüttgert, Katja ^a   Schott, Eckart ^a   Neuhaus, Peter ^a   Stockmann, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

chronic liver disease; liver function; liver function test; methacetin; prognosis; survival; transplantation

Indexed keywords

BILIRUBIN; INDOCYANINE GREEN; 4 ACETANISIDINE; ACETAMIDE DERIVATIVE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; END STAGE LIVER DISEASE; FOLLOW UP; GRAFT RECIPIENT; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CLEARANCE; LIVER FUNCTION TEST; LIVER GRAFT; MAXIMUM LIVER FUNCTION CAPACITY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SHORT TERM SURVIVAL; CHEMISTRY; FEMALE; INTERNATIONAL NORMALIZED RATIO; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ACETAMIDES; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTERNATIONAL NORMALIZED RATIO; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84916213516     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12441     Document Type: Article

References (30)

1. Botta F, Giannini E, Romagnoli P, et al,. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52: 134.
2. Angermayr B, Cejna M, Karnel F, et al,. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879.
3. Wiesner R, Edwards E, Freeman R, et al,. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91.
4. Al-Freah MA, Kriese S, Foxton MR, et al,. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013; 26: 1070.
5. Walker NM, Stuart KA, Ryan RJ, et al,. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683.
6. Hoyer DP, Paul A, Gallinat A, et al,. Donor information based prediction of early allograft dysfunction and outcome in liver transplantation. Liver Int 2013. doi: 10.1111/liv.12443. [Epub ahead of print].
7. Stockmann M, Lock JF, Riecke B, et al,. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119.
8. Lock JF, Schwabauer E, Martus P, et al,. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010; 16: 172.
9. Lock JF, Malinowski M, Schwabauer E, et al,. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week. Clin Transplant 2011; 25: 436.
10. Lock JF, Kotobi AN, Malinowski M, et al,. Predicting the prognosis in acute liver failure: results from a retrospective pilot study using the LiMAx test. Ann Hepatol 2013; 12: 556.
11. Leevy CM, Smith F, Longueville J, Paumgartner G, Howard MM,. Indocyanine green clearance as a test for hepatic function. Evaluation by dichromatic ear densitometry. JAMA 1967; 200: 236.
12. Cherrick GR, Stein SW, Leevy CM, Davidson CS,. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960; 39: 592.
13. Mizushima Y, Tohira H, Mizobata Y, Matsuoka T, Yokota J,. Assessment of effective hepatic blood flow in critically ill patients by noninvasive pulse dye-densitometry. Surg Today 2003; 33: 101.
14. Sakka SG,. Assessing liver function. Curr Opin Crit Care 2007; 13: 207.
15. Drobatz KJ,. Measures of accuracy and performance of diagnostic tests. J Vet Cardiol 2009; 11 (Suppl. 1): S33.
16. Stockmann M, Lock JF, Malinowski M, Niehues SM, Seehofer D, Neuhaus P,. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010; 12: 139.
17. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307.
18. Schaubel DE, Guidinger MK, Biggins SW, et al,. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9: 970.
19. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al,. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46.
20. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217.
21. Kim WR, Biggins SW, Kremers WK, et al,. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018.
22. Zipprich A, Kuss O, Rogowski S, et al,. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut 2010; 59: 963.
23. Merkel C, Gatta A, Zoli M, et al,. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991; 36: 1197.
24. Stauber RE, Wagner D, Stadlbauer V, et al,. Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. Liver Int 2009; 29: 1516.
25. Sakka SG, Hofmann D, Thuemer O, Schelenz C, van Hout N,. Increasing cardiac output by epinephrine after cardiac surgery: effects on indocyanine green plasma disappearance rate and splanchnic microcirculation. J Cardiothorac Vasc Anesth 2007; 21: 351.
26. Seibel A, Muller A, Sakka SG,. Indocyanine green plasma disappearance rate for monitoring hepatosplanchnic blood flow. Intensive Care Med 2011; 37: 357.
27. Stockmann M, Malinowski M, Lock JF, Seehofer D, Neuhaus P,. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology 2009; 56: 734.
28. Biggins SW, Bambha K,. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006; 26: 211.
29. Moore KP, Aithal GP,. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 (Suppl. 6): vi1.
30. Riordan SM, Williams R,. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473.